125 related articles for article (PubMed ID: 27363336)
1. High-throughput screening identifies artesunate as selective inhibitor of cancer stemness: Involvement of mitochondrial metabolism.
Subedi A; Futamura Y; Nishi M; Ryo A; Watanabe N; Osada H
Biochem Biophys Res Commun; 2016 Sep; 477(4):737-742. PubMed ID: 27363336
[TBL] [Abstract][Full Text] [Related]
2. Induced cancer stem-like cells as a model for biological screening and discovery of agents targeting phenotypic traits of cancer stem cell.
Nishi M; Akutsu H; Kudoh A; Kimura H; Yamamoto N; Umezawa A; Lee SW; Ryo A
Oncotarget; 2014 Sep; 5(18):8665-80. PubMed ID: 25228591
[TBL] [Abstract][Full Text] [Related]
3. A novel inhibitor of tumorspheres reveals the activation of the serine biosynthetic pathway upon mitochondrial inhibition.
Subedi A; Muroi M; Futamura Y; Kawamura T; Aono H; Nishi M; Ryo A; Watanabe N; Osada H
FEBS Lett; 2019 Apr; 593(8):763-776. PubMed ID: 30874300
[TBL] [Abstract][Full Text] [Related]
4. Targeting flavin-containing enzymes eliminates cancer stem cells (CSCs), by inhibiting mitochondrial respiration: Vitamin B2 (Riboflavin) in cancer therapy.
Ozsvari B; Bonuccelli G; Sanchez-Alvarez R; Foster R; Sotgia F; Lisanti MP
Aging (Albany NY); 2017 Dec; 9(12):2610-2628. PubMed ID: 29253841
[TBL] [Abstract][Full Text] [Related]
5. FOXM1-Induced PRX3 Regulates Stemness and Survival of Colon Cancer Cells via Maintenance of Mitochondrial Function.
Song IS; Jeong YJ; Jeong SH; Heo HJ; Kim HK; Bae KB; Park YH; Kim SU; Kim JM; Kim N; Ko KS; Rhee BD; Han J
Gastroenterology; 2015 Oct; 149(4):1006-16.e9. PubMed ID: 26091938
[TBL] [Abstract][Full Text] [Related]
6. Exploiting mitochondrial targeting signal(s), TPP and bis-TPP, for eradicating cancer stem cells (CSCs).
Ozsvari B; Sotgia F; Lisanti MP
Aging (Albany NY); 2018 Feb; 10(2):229-240. PubMed ID: 29466249
[TBL] [Abstract][Full Text] [Related]
7. Eucommicin A, a β-truxinate lignan from Eucommia ulmoides, is a selective inhibitor of cancer stem cells.
Fujiwara A; Nishi M; Yoshida S; Hasegawa M; Yasuma C; Ryo A; Suzuki Y
Phytochemistry; 2016 Feb; 122():139-145. PubMed ID: 26678322
[TBL] [Abstract][Full Text] [Related]
8. Construction and application of a lung cancer stem cell model: antitumor drug screening and molecular mechanism of the inhibitory effects of sanguinarine.
Yang J; Fang Z; Wu J; Yin X; Fang Y; Zhao F; Zhu S; Li Y
Tumour Biol; 2016 Oct; 37(10):13871-13883. PubMed ID: 27485114
[TBL] [Abstract][Full Text] [Related]
9. Identification of heat shock protein 90 inhibitors to sensitize drug resistant side population tumor cells using a cell based assay platform.
Sobhan PK; Seervi M; Joseph J; Chandrika BB; Varghese S; Santhoshkumar TR; Radhakrishna Pillai M
Cancer Lett; 2012 Apr; 317(1):78-88. PubMed ID: 22085491
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial biology in cancer stem cells.
Loureiro R; Mesquita KA; Magalhães-Novais S; Oliveira PJ; Vega-Naredo I
Semin Cancer Biol; 2017 Dec; 47():18-28. PubMed ID: 28673608
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrially targeted vitamin E succinate efficiently kills breast tumour-initiating cells in a complex II-dependent manner.
Yan B; Stantic M; Zobalova R; Bezawork-Geleta A; Stapelberg M; Stursa J; Prokopova K; Dong L; Neuzil J
BMC Cancer; 2015 May; 15():401. PubMed ID: 25967547
[TBL] [Abstract][Full Text] [Related]
12. Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation.
Kim MJ; Koo JE; Han GY; Kim B; Lee YS; Ahn C; Kim CW
J Korean Med Sci; 2016 Mar; 31(3):360-70. PubMed ID: 26955235
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic screening reveals topoisomerase I as a breast cancer stem cell therapeutic target.
Zhang F; Rothermund K; Gangadharan SB; Pommier Y; Prochownik EV; Lazo JS
Oncotarget; 2012 Sep; 3(9):998-1010. PubMed ID: 22948175
[TBL] [Abstract][Full Text] [Related]
14. Mitochondria in cancer stem cells: Achilles heel or hard armor.
Zheng XX; Chen JJ; Sun YB; Chen TQ; Wang J; Yu SC
Trends Cell Biol; 2023 Aug; 33(8):708-727. PubMed ID: 37137792
[TBL] [Abstract][Full Text] [Related]
15. Smad inhibitor induces CSC differentiation for effective chemosensitization in cyclin D1- and TGF-β/Smad-regulated liver cancer stem cell-like cells.
Xia W; Lo CM; Poon RYC; Cheung TT; Chan ACY; Chen L; Yang S; Tsao GSW; Wang XQ
Oncotarget; 2017 Jun; 8(24):38811-38824. PubMed ID: 28415588
[TBL] [Abstract][Full Text] [Related]
16. Cytoprotective effect of neuropeptides on cancer stem cells: vasoactive intestinal peptide-induced antiapoptotic signaling.
Sastry KS; Chouchane AI; Wang E; Kulik G; Marincola FM; Chouchane L
Cell Death Dis; 2017 Jun; 8(6):e2844. PubMed ID: 28569785
[TBL] [Abstract][Full Text] [Related]
17. Glycophenotype of breast and prostate cancer stem cells treated with thieno[2,3-
Mastelić A; Čikeš Čulić V; Režić Mužinić N; Vuica-Ross M; Barker D; Leung EY; Reynisson J; Markotić A
Drug Des Devel Ther; 2017; 11():759-769. PubMed ID: 28352152
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells.
De Luca A; Fiorillo M; Peiris-Pagès M; Ozsvari B; Smith DL; Sanchez-Alvarez R; Martinez-Outschoorn UE; Cappello AR; Pezzi V; Lisanti MP; Sotgia F
Oncotarget; 2015 Jun; 6(17):14777-95. PubMed ID: 26087310
[TBL] [Abstract][Full Text] [Related]
19. Cuprous oxide nanoparticle-inhibited melanoma progress by targeting melanoma stem cells.
Yu B; Wang Y; Yu X; Zhang H; Zhu J; Wang C; Chen F; Liu C; Wang J; Zhu H
Int J Nanomedicine; 2017; 12():2553-2567. PubMed ID: 28435246
[TBL] [Abstract][Full Text] [Related]
20. Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition.
Lamb R; Harrison H; Hulit J; Smith DL; Lisanti MP; Sotgia F
Oncotarget; 2014 Nov; 5(22):11029-37. PubMed ID: 25415228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
